Chronic eye irritation that never quite goes away often has a simple, overlooked source: the eyelid margin itself.
Blepharitis is inflammation of the lid margin, and it is one of the most common conditions seen in any eye clinic.
It rarely threatens vision directly, but it drives a disproportionate share of chronic ocular surface complaints.
Patients often cycle through artificial tears and antibiotic drops without lasting relief because the underlying lid margin disease is never specifically addressed.
Blepharitis is not a single disease — it spans several distinct mechanisms, from bacterial colonization to meibomian gland dysfunction to Demodex mite infestation.
Correctly classifying which type (or combination) a patient has is what actually determines whether treatment works.
What Is Blepharitis?
Blepharitis is a chronic inflammatory condition of the eyelid margin, broadly divided by anatomic location.
The two principal forms are:
- Anterior blepharitis — affects the eyelid skin, lash follicles, and lash base; further subdivided into staphylococcal and seborrheic types
- Posterior blepharitis — affects the meibomian glands, and largely overlaps with meibomian gland dysfunction (MGD)
Many patients have mixed anterior and posterior disease, and Demodex mite infestation can contribute to either form.
Epidemiology
Blepharitis is extremely common and likely underreported, since many patients simply live with mild symptoms.
- It is among the most frequent reasons for referral to eye care for ocular surface complaints
- Prevalence increases with age, and posterior blepharitis/MGD becomes proportionally more common in older adults
- Demodex folliculorum and Demodex brevis mite colonization increases markedly with age and is found in a substantial proportion of adults over 60, though colonization alone does not equal disease
Because blepharitis is chronic and relapsing rather than curable, most patients require ongoing lid hygiene rather than a single course of treatment.
Pathophysiology
The mechanism differs meaningfully between the two anatomic forms.
- Staphylococcal anterior blepharitis involves chronic bacterial colonization of the lash follicles, provoking a low-grade inflammatory and sometimes toxin-mediated reaction
- Seborrheic anterior blepharitis is associated with excess sebaceous gland secretion and is often linked to seborrheic dermatitis elsewhere on the skin
- Posterior blepharitis/MGD results from obstruction and qualitative change in meibomian gland secretions, which destabilizes the tear film lipid layer
- Demodex folliculorum preferentially colonizes the lash base, contributing to anterior disease, while Demodex brevis inhabits the meibomian glands, contributing to posterior disease
Whichever mechanism dominates, the end result is the same: an unstable tear film, chronic surface inflammation, and recurrent symptoms.
Risk Factors
Ocular Risk Factors
- Pre-existing dry eye disease or tear film instability
- Rosacea-associated ocular surface disease
- Contact lens wear
- History of chalazia, which frequently coexist with untreated MGD
Demographic and Systemic Risk Factors
- Increasing age
- Seborrheic dermatitis
- Diabetes, which is associated with a higher burden of MGD in some studies
Because most risk factors are chronic rather than acute, blepharitis management is realistically about long-term control, not a one-time cure.
Clinical Presentation
Symptoms
- Burning, itching, or a foreign-body sensation, typically worse in the morning
- Eyelid crusting on waking, sometimes with lashes matted together
- Redness of the lid margins
- Fluctuating, mildly blurred vision related to an unstable tear film
- Chronic, relapsing course with symptom-free intervals
Examination Findings
Findings vary by subtype:
- Cylindrical collarettes wrapped around the lash base — characteristic of Demodex infestation
- Hard, brittle crusts and occasional lash loss or misdirection — typical of staphylococcal blepharitis
- Greasy, scaly debris along the lid margin — typical of seborrheic blepharitis
- Thickened, irregular lid margins with plugged or capped meibomian gland orifices — typical of posterior blepharitis/MGD
- Reduced or poor-quality meibum expression on gentle lid pressure
Careful slit-lamp inspection of the lash base and gland orifices — not just the general appearance of redness — is what actually distinguishes the subtypes.
Diagnostic Evaluation
Slit-Lamp Examination
- Direct inspection of lash base, lid margin, and meibomian gland orifices remains the primary diagnostic tool
- Epilation of a lash for microscopic examination can confirm Demodex when collarettes are seen but the diagnosis is uncertain
Tear Film Assessment
- Tear break-up time is often reduced given the frequent overlap with evaporative dry eye
- Meibomian gland expression assesses secretion quality and gland patency
No laboratory test is routinely required — blepharitis remains a clinical diagnosis made at the slit lamp.
Differential Diagnosis
Conditions that can mimic or coexist with blepharitis include:
- Dry eye disease — often coexists with and is worsened by blepharitis, rather than being a true mimic
- Chalazion/hordeolum — focal nodules rather than diffuse lid margin change
- Allergic conjunctivitis — itching predominates, with conjunctival rather than lid margin findings
- Herpes simplex or zoster blepharitis — vesicular lesions and a more acute, often unilateral presentation
- Sebaceous gland carcinoma — must be considered in unilateral, treatment-resistant, or atypical chronic blepharitis, particularly in older patients
Distinguishing routine blepharitis from these mimics avoids both undertreating a masquerading tumor and overtreating a self-limited condition.
Management
Lid Hygiene
The foundation of treatment for essentially all forms of blepharitis:
- Warm compresses to soften debris and improve meibomian gland secretion flow
- Gentle lid margin cleansing with diluted baby shampoo, commercial lid wipes, or lid-cleansing foam
- Consistent, long-term use rather than short courses, since blepharitis is a chronic relapsing condition
Demodex-Directed Therapy
- Tea tree oil or its active component terpinen-4-ol has traditionally been used for Demodex-associated blepharitis
- Topical lotilaner ophthalmic solution is a newer, FDA-approved, targeted treatment specifically for Demodex blepharitis
- Second-line options reported in the literature include ivermectin and metronidazole preparations
Pharmacologic and Adjunctive Therapy
- Topical or oral antibiotics (e.g., doxycycline) for moderate-to-severe staphylococcal or MGD-related disease, exploiting their anti-inflammatory as well as antibacterial effects
- Short courses of topical corticosteroids for significant inflammation, used cautiously given long-term side effects
- In-office procedures such as meibomian gland expression or thermal pulsation for refractory MGD
Treatment should always target the dominant mechanism in a given patient rather than applying a single generic regimen to every case.
Prognosis
Blepharitis is a chronic, relapsing condition rather than one that is definitively cured.
- Most patients achieve good symptom control with consistent lid hygiene and appropriate targeted therapy
- Symptoms tend to recur when hygiene measures lapse
- Vision-threatening complications are uncommon but can include corneal changes from chronic marginal keratitis or tear film instability in severe, longstanding cases
Setting expectations around long-term maintenance, rather than a one-time cure, is central to keeping patients engaged in treatment.
Would you like to document anterior segment findings with your smartphone?
Smartphone slit-lamp photography makes it easy to capture lid margin crusting and collarettes and track response to treatment over time using a simple slit-lamp adaptor.
SLIT-LAMP SMARTPHONE PHOTOGRAPHY
References
- American Academy of Ophthalmology. Blepharitis Preferred Practice Pattern. 2024.
- Trattler W, Karpecki P, Rapoport Y, et al. The prevalence of Demodex blepharitis in US eye care clinic patients. Clinical Ophthalmology. 2022.
- Yeu E, Wirta DL, Karpecki P, et al. Lotilaner ophthalmic solution 0.25% for the treatment of Demodex blepharitis: the Saturn-1 and Saturn-2 trials. Cornea. 2023.
- Cheng AM, Sheha H, Tseng SC. Recent advances on ocular Demodex infestation. Current Opinion in Ophthalmology. 2015.
- Update on the Management of Demodex Blepharitis. Cornea. 2024.
- Blepharitis. EyeWiki, American Academy of Ophthalmology.
